Hively Brad's Form 4 filing
Starling Oncology, Inc. (DFPH) · filed Aug 24, 2026
- Accession no.
- 0001079973-26-001175
- Filed
- Aug 24, 2026, 5:11 PM ET
- Trade date
- Aug 21, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.95M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hively BradCIK 0001891124 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Common Stock | SSaleDisposed | −298,853 | $6.51F1 | −$1,946,310.05 | 411,976 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
Referenced by the price of 1 transaction in Table I.